Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

DOI https://doi.org/10.4081/reumatismo.2014.799

Article Sidebar

PDF
Published: Mar 31, 2015
Reviews

Issue
Vol 66, No 4 (2014)
Pages
285-303
Keywords
Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.
Statistics
Abstract Views: 1361

PDF: 1502
Share it
How to Cite
Rossini, M., Viapiana, O., Orsolini, G., Fracassi, E., Idolazzi, L., Gatti, D., Adami, S., & Govoni, M. (2015). Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo, 66(4), 285-303. https://doi.org/10.4081/reumatismo.2014.799
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Main Article Content

M. Rossini *
Rheumatology Unit, University of Verona, Italy.
O Viapiana
Rheumatology Unit, University of Verona, Italy.
G. Orsolini
Rheumatology Unit, University of Verona, Italy.
E. Fracassi
Rheumatology Unit, University of Verona, Italy.
L. Idolazzi
Rheumatology Unit, University of Verona, Italy.
D. Gatti
Rheumatology Unit, University of Verona, Italy.
S. Adami
Rheumatology Unit, University of Verona, Italy.
M. Govoni
Rheumatology Unit, University of Ferrara, Italy.
(*) Corresponding Author:
M. Rossini | maurizio.rossini@univr.it

Abstract

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)